Skip to content

Assessing the Role of Mitochondrial Dysfunction in Primary Progressive Multiple Sclerosis

Assessing the Role of Mitochondrial Dysfunction in Primary Progressive Multiple Sclerosis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06025903
Enrollment
140
Registered
2023-09-06
Start date
2021-09-20
Completion date
2025-05-30
Last updated
2024-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Keywords

multiple sclerosis, mitochondria

Brief summary

The purpose of this project is to study genetic determinants of mitochondrial impairment in primary progressive multiple sclerosis. Specific aims are: 1) identify mitochondrial-related pathways, inherited and somatic mitochondrial DNA mutations associated to primary progressive multiple sclerosis, 2) functionally assess the identified genetic alterations.

Detailed description

Multiple Sclerosis is a major cause of neurological disability, with a high socio-economic impact that increases as disability progresses. Effective treatment of primary progressive multiple sclerosis is still an unmet need and the underlying neurodegenerative processes have to be fully investigated. The purpose of this project is to study genetic determinants of mitochondrial impairment in primary progressive multiple sclerosis. Altered mitochondrial pathways will be investigate, as well as inherited and tissue-specific somatic mitochondrial variations associated with primary progressive multiple sclerosis.

Interventions

None listed

Sponsors

Azienda Socio Sanitaria Territoriale della Valle Olona
CollaboratorOTHER
IRCCS San Raffaele
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients affected by primary progressive or relapsing remitting multiple sclerosis * Patient able to provide informed consent

Exclusion criteria

* Individuals with \< 18 years * Patients not affected by primary progressive or relapsing remitting multiple sclerosis

Design outcomes

Primary

MeasureTime frameDescription
sequencing of mitochondrial DNA3 yearsthe mitochondrial DNA collected from blood and cerebrospinal fluid will be sequenced and analysed, comparing the frequency of variants between the two disease courses

Countries

Italy

Contacts

Primary ContactFederica Esposito
esposito.federica@hsr.it0226437833

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026